Breathe Well Live Well
Conditions: Severe Persistent Asthma; Eosinophilic Bronchitis
Interventions: Biological: Reslizumab; Drug: Placebo
Sponsors: McMaster University; Teva Pharmaceuticals USA; St. Joseph’s Healthcare Hamilton
Not yet recruiting – verified September 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Monoclonal Antibody Dupilumab Safe And Effective In Asthma Phase IIa Trial
Science 2.0 A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to researchers. The randomized, double-blind, placebo-controlled trial tested the efficacy … |
View full post on asthma – Google News
|
KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal …
The Herald | HeraldOnline.com KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma … |
View full post on asthma – Google News
 Examiner.com |
Monoclonal Antibody Works in Severe Asthma
MedPage Today Note that a multicenter, randomized placebo-controlled trial found that mepolizumab, a monoclonal antibody against interleukin-5, decreased asthma exacerbations, hospitalizations, and emergency department visits for patients with severe asthma and … Clinical study: New asthma drug cuts attack frequency in half GSK severe asthma drug progresses to Phase III GSK asthma drug cuts symptoms 52%; ready for PhIII |
View full post on asthma – Google News
|
Humanized Monoclonal Antibody May Be Effective, Safe in Asthma Patients
Medscape January 11, 2011 — Add-on therapy with subcutaneous omalizumab is safe and effective in patients with moderate to severe allergic asthma, according to the … |
View full post on asthma – Google News